On December 4, 2019 Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, reported that new data will be presented from its KA2237 Phase I study at the ASH (Free ASH Whitepaper) Annual Meeting & Exposition in Orlando, Florida, 9 December 2019 (Press release, Karus Therapeutics, DEC 4, 2019, View Source [SID1234551928]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients with relapsed/refractory B-cell lymphoma.
KA2237 is a potent, orally-active and dual-selective PI3 Kinase (PI3K) p110β/δ inhibitor. The p110δ isoform is an attractive therapeutic target, with several known inhibitors demonstrating efficacy in B-cell lymphomas. Karus aims to overcome mechanisms of tumor escape by simultaneously targeting PI3K p110β.
Tim Edwards, Karus’ Executive Chairman, commented:
"As we continue in our mission to develop transformative precision medicines for cancer, ASH (Free ASH Whitepaper) provides the perfect opportunity to showcase the potential of KA2237 in the treatment of hematological and solid tumors. We are pleased to be presenting our new data and look forward to connecting with more of the hematology community."
Details of the poster presentation are as follows:
Title: 4099. Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma
Time and Date: 18:00–20:00, Monday 9 December
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster III
Presenters: Dr Loretta Nastoupil, MD (on behalf of MD Anderson Cancer Center) and Dr Philip Beer, MD, PhD (on behalf of Karus).